EMVISION COMMENCES CLINICAL TRIAL
EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to provide a clinical trial update. The Company has received the administrative “green light” activation and has now commenced its clinical trial and scanning of stroke patients at the Princess Alexandra Hospital. EMVision CEO, Dr Weinberger, commented “Taking a prototype of our complexity from the lab to a device that is designed for and meets the needs of a clinical trial in 12 months, is a significant feat in our industry. Now, as we commence our pilot clinical trial, we embark on a major step forward for the diagnosis and monitoring of stroke, at the point of care, in a manner otherwise not possible today.” For more information about the trial, please refer to the ‘Clinical Trial Summary’ provided in the ASX Announcement dated 19th December 2019.
The Company has started its clinical trial and scanning of stroke patients at the Princess Alexandra Hospital. It is seeking to commercialise a cost effective, portable, medical device using microwave imaging for diagnosis and monitoring of stroke and other medical applications.